[go: up one dir, main page]

WO1998049279A1 - Utilisation de detergent/tensioactiof zwitterionique pour purifier l'acide glutamique decarboxylase (gad) et composition contenant cette enzyme gad - Google Patents

Utilisation de detergent/tensioactiof zwitterionique pour purifier l'acide glutamique decarboxylase (gad) et composition contenant cette enzyme gad Download PDF

Info

Publication number
WO1998049279A1
WO1998049279A1 PCT/SE1998/000723 SE9800723W WO9849279A1 WO 1998049279 A1 WO1998049279 A1 WO 1998049279A1 SE 9800723 W SE9800723 W SE 9800723W WO 9849279 A1 WO9849279 A1 WO 9849279A1
Authority
WO
WIPO (PCT)
Prior art keywords
surfactant
zwitterionic detergent
gad
composition
glutamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1998/000723
Other languages
English (en)
Inventor
John Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diamyd Therapeutics AB
Original Assignee
Diamyd Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9701564A external-priority patent/SE9701564D0/xx
Priority claimed from SE9800256A external-priority patent/SE9800256D0/xx
Priority claimed from SE9800735A external-priority patent/SE9800735D0/xx
Application filed by Diamyd Therapeutics AB filed Critical Diamyd Therapeutics AB
Priority to EP98920768A priority Critical patent/EP0977835A1/fr
Priority to AU73532/98A priority patent/AU7353298A/en
Publication of WO1998049279A1 publication Critical patent/WO1998049279A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • GAD glutamic acid decarboxylase
  • the present invention relates to a novel and improved method of producing glutamic acid decarboxylase.
  • the invention relates to a novel procedure for purifying the enzyme from recombinant cells engineered to produce the enzyme or from native cells or tissues containing it.
  • IDDM Insulin-dependent diabetes mellitus
  • One therapeutic strategy is aimed at preventing autoimmune destruction of pancreatic beta cells via a process of "tolerisation” whereby treatment with specific autoantigens can result in immunological "re-programming” to re-establish appropriate "self from "non-self distinction.
  • GAD glutamic acid decarboxylase
  • GAD antibodies and GAD-reactive T-cells identifies this protein as an autoantigen and implicates its involvement in the autoimmune destruction of pancreatic beta cells - the patho-aetiological "hallmark" of IDDM.
  • 89:2115-2119 used a 180 bp fragment of the rat GAD65 cDNA sequence (Eriander et al. 1991 Neuron 7:91-100 all of which are incorporated by reference) to probe a human hippocampus cDNA library.
  • Non-ionic detergents Triton X-100, Triton X-l 14 and n-octylglucoside, as well as the ionic detergent: sodium dodecyl sulphate - are also specified in WO95/04137
  • Tritons are not chemically-defined (thereby imposing difficulties regarding definition of a GMP-compliant process)
  • Triton-solubilised proteins (including rhGAD65) are not easily dialysed or ultrafiltered. Accordingly, the inclusion of Triton X-l 14 is likely to complicate downstream processing of rhGAD65.
  • Triton X-l 14-extracted insect cells expressing rhGAD65 have been found to have high viscosity - resulting in prolongation of chromatographic application times (by imposing extremely low chromatographic flow-rates). Consequently, the use of Triton X-l 14 extends run times considerably, and its inclusion is assessed by us as not enabling a cost-effective process.
  • Triton X-l 14 extraction method was discovered by us to result in the co- extraction of the baculoviral glycoprotein "gp64" with rhGAD65. Furthermore, as these two proteins are not readily distinguishable (they co- migrate in SDS-PAGE) it is considered advantageous to avoid their co- purification at an early purification stage.
  • Triton X-l 14 extraction method of Bordier (1981) involves 1-3 condensation steps - whereby the detergent-rich phase containing solubilised hydrophobic proteins (i.e. including rhGAD65) is separated from hydrophilic proteins in the water-rich phase (by lowering the temperature below the "cloud point" of 20°C).
  • This method therefore, is not readily-scaleable, and inclusion of Triton X-l 14 condensation steps for extraction and partial purification will significantly lengthen a commercial manufacturing process.
  • n-octylglucoside this is regarded as an inferior detergent due its high cost and because it readily allows microbial growth, and is not therefore conducive to a scaled-up manufacturing process.
  • sodium dodecyl sulphate it is relevant to mention that this is reported (in WO95/04137) as effective at 0.1%, but completely eliminates rhGAD65 enzyme activity at 1.0%.
  • x is an integer from 1 to 5 and y is an integer from 2 to 20, such as N- dodecyl-N,N-dimethyl-3-ammonio-l -propane sulphonate, surprisingly good purification results are achieved at the same time as most of the above mentioned problems are solved.
  • the zwitterionic detergent is preferably used both when extracting proteins from GAD-containing cells and during subsequent purification steps, such as ion exchange chromatography.
  • the use of the zwitterionic detergent/surfactant surprisingly provides an internal reference check of IEX resolution as it separates another, ca. 65kDa baculoviral chitinase protein from rhGAD 65. This chitinase protein is different from the earlier mentioned baculovims 64 kDa glycoprotein and is likely to remain a contaminant in rhGAD 65 preparations where Triton or Octylglucoside have been used.
  • the present invention relates to using a zwitterionic detergent/surfactant, preferably of a type disclosed in the appended claims 4-5, in a process for purifying glutamic acid decarboxylase (GAD).
  • GAD glutamic acid decarboxylase
  • the invention also relates to compositions obtainable by the process, which compositions comprises GAD and a zwitterionic detergent/surfactant. These compositions are suitable as pharmaceutical for treating IDDM, cancer, etc. They can also be used as vaccine compositions against autoimmune diseases such as IDDM, rheumatoid arthritis etc. Moreover, the compositions can be used for determining the presence of antibodies against glutamic acid decarboxylase (GAD). Such assays are valuable when diagnosing autoimmune diseases.
  • compositions are suitable as pharmaceutical agents for treating Stiff Man Syndrome and Graves' disease, They can also be used in vaccine compositions against Coxsackie virus, polio, mumps, parotis and rubella.
  • HEPES buffer at 50 mM and pH 7.2 has been successfully used in studies of GAD from murine brain (Meeley & Martin (1983) Cellular & Molec Neurobiol. 3(l):55-68) and pig brain (Porter & Martin (1988) J. Neurochem. 51(6): 1886-91). HEPES has also been used for initial fractionation of rhGAD65 from insect cells (10 mm used by Christgau et al. 1992 J. Cell. Biol. 118(2):309- 320; all of which are incorporated by reference).
  • DTT Reducing agents are frequently used for stabilisation during extraction and purification of proteins, and use of DTT has been recommended for protein stabilisation during detergent extiaction (Hjelmeland and Chrambach 1984 Methods Enzymol. 114:305-318).
  • a high concentration of DTT 50 mM
  • Zwittergen 3-12 for purification ofthe human interferon "Betaseron” (Russel-Harde et al. 1995 J. Interferon & Cytokine Res. 15:31-37, all of which are incorporated by reference).
  • a reducing agent is included to minimise inter- and intra-molecular disulphide bridge formation by maintaining thiol groups (cyteine residues) in their reduced state.
  • thiol groups cyteine residues
  • PBP Pyridoxal-5 -phosphate
  • This stabilising agent has also used (at 0.5 mM) for extraction of GAD from human brain (Blinderman et al. (1978) Eur. J. Biochem. 86: 143-152); for rat brain (used at 0,2 mM by Wu et al. (1985) Methods Enzymology 113:3-10); and for bovine brain (used at 0,2 mM by Wu (1982) Proc. Natl. Acad. Sci. USA 79:4270-4, all of which are incorporated by reference).
  • Use of 0.2-1.0 mM PLP is also mentioned in WO95/04137.
  • protease inhibitors are often mandatory in the extraction and purification of recombinant proteins from eukaryotic expression systems.
  • certain of these e.g. APMSF
  • APMSF e.g. APMSF
  • the separate addition of individual protease inhibitors prior to cell extraction was unattractive during the design of our process, and has been avoided by us by the addition of single tablets of a pre-made "cocktail" of complete protease inhibitors.
  • Fig. 1 shows a Western blot disclosing the presence absence of GAD in a cell homogenate and in the supernatant as well as in the pellet after the cell homogenate has been ultracentrifugated.
  • the cell homogenate has been prepared according to the present invention.
  • Fig 2 discloses the result of an ion exchange chromatography purification step ac- cording to a preferred embodiment of the present invention
  • Fig 3 illustrates the degree of purification after ion exchange chromatography by showing an electrophoresis gel in which lane 1 corresponds to unpurified protein extract and lanes 2-6 correspond to different dilutions of the purified rhGAD65 enzyme;
  • Fig 4 discloses rhGAD65 -specific immunoreactivity by Western blotting.
  • Recombinant cells expressing GAD were prepared as disclosed in Christgau et al.,
  • Zwittergent 3-12 N-Dodecyl-N,N-dimethyl-3-ammonio-l-propansulphonate
  • HEPES 119.15 g was dissolved in 350 ml sterile distilled water. pH was adjusted to 7.2. The volume was adjusted to 500 ml and the buffer was passed through a sterile filter, 0.2 microns.
  • Ion-exchange chromatography using Source Q 15 was used for "capture” and first purification of rhGAD65 from extracts of GAD-infected Sf9 cells. Briefly, after extract loading and column washing (10 bed volumes), a gradient to 0.3 M NaCI (over 10 bed volumes) was started, which caused elution of rhGAD65 as a component of the first of two major UV-absorbing peaks at 0J5 M salt. All fractions were collected, aliquots from all fractions removed for analysis to locate eluate fractions with rhGAD65, and all fractions/aliquots were frozen/stored at - 70°C. The aliquots alone (that had been removed from their respective fractions at the time of collection) were then thawed and analysed.
  • fractions were selected to maximise GAD concenhation (i.e. those with maximal staining intensity of GAD65 band in SDS-PAGE, Western immunoblot, and enzyme activity) while simultaneously minimising protein contaminants. These contaminants were defined as bands visualised on SDS-PAGE gels (e.g. see Fig. 5.5) that do not bind GAD65 antibodies on Western analysis (e.g. see Fig. 5.6). Selected fractions were then thawed, bulked, and immediately refrozen (and stored at -70°C) to provide IEX- purified rhGAD65.
  • Zwittergent 3-12 N-Dodecyl-N,N-dimethyl-3-ammonio-l -propane sulphonate
  • Zwittergent 3-12 1.5 g pH was adjusted to 7.2 with cone. Hcl. Adjust the volume to 1000 ml.
  • Buffer B (was as Buffer A (above) containing 0.3 M NaCI. Condutivity was ca: 20 mS/cm)
  • the buffer was prepared as Buffer A. NaCI was added before adjusting pH and vo- lume.
  • the buffer was prepared as Buffer A. 3 "Complete" tablets was added for every 125 ml of buffer. Sample preparation
  • the FPLC system included the simultaneous and continuous measurement and display of the following run parameters :
  • the IEX system used was FPLC (Pharmacia, SE), and the chromatography was largely carried out according to the manufacturer's recommendations.
  • Fig. 2 discloses the salt gradient part ofthe obtained chromatogram.
  • the GAD enzyme activity of the eluted fractions were determined according to Blindermann et al (1978)., Eur. J. Biochem. 86: 143-152. The results are both presented in the following table, and in Fig. 2.
  • the activity peak in Fig. 2 is situated about two fractions after the main peak. This is due to the amount of eluate between the OD 280 detector and the fraction collector. Hence, the main peak and the activity peak are closely correlated.
  • Fig. 3 discloses an SDS-PAGE gel in which lane 1 corresponds to unpurified protein extract and lanes 2-7 correspond to different dilutions of fraction 61 showing the highest degree of purity.
  • Fig. 4 discloses the result of Western blotting of fractions 55-97. rhGAD65 is only present in fractions 59-63.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'extraction et la purification d'acide glutamique décarboxylase sont améliorées par l'utilisation de solutions tampons contenant des détergents/tensioactifs zwittérioniques, de préférence, selon la formule chimique suivante: CyH2y+1 - N+(CH3)2 - CxH2x - SO3- où x est un nombre entier compris entre 1 et 5 et y un nombre entier compris entre 2 et 20.
PCT/SE1998/000723 1997-04-25 1998-04-21 Utilisation de detergent/tensioactiof zwitterionique pour purifier l'acide glutamique decarboxylase (gad) et composition contenant cette enzyme gad Ceased WO1998049279A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98920768A EP0977835A1 (fr) 1997-04-25 1998-04-21 Utilisation de detergent/tensioactiof zwitterionique pour purifier l'acide glutamique decarboxylase (gad) et composition contenant cette enzyme gad
AU73532/98A AU7353298A (en) 1997-04-25 1998-04-21 Use of a zwitterionic detergent/surfactant for purifying glutamic acid decarboxylase (gad) and a composition containing gad

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE9701564-8 1997-04-25
SE9701564A SE9701564D0 (sv) 1997-04-25 1997-04-25 New process
SE9800256A SE9800256D0 (sv) 1998-01-29 1998-01-29 New process
SE9800256-1 1998-01-29
SE9800735-4 1998-03-06
SE9800735A SE9800735D0 (sv) 1998-03-06 1998-03-06 New process

Publications (1)

Publication Number Publication Date
WO1998049279A1 true WO1998049279A1 (fr) 1998-11-05

Family

ID=27355869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/000723 Ceased WO1998049279A1 (fr) 1997-04-25 1998-04-21 Utilisation de detergent/tensioactiof zwitterionique pour purifier l'acide glutamique decarboxylase (gad) et composition contenant cette enzyme gad

Country Status (3)

Country Link
EP (1) EP0977835A1 (fr)
AU (1) AU7353298A (fr)
WO (1) WO1998049279A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027496A1 (fr) * 1998-11-09 2000-05-18 Knut Irgum Procede de chromatographie, et substance de garniture de la colonne utilisee dans le cadre dudit procede
EP1606404A4 (fr) * 2003-03-12 2006-04-12 Assay Designs Inc Dosage de phosphokinase
CN103305495A (zh) * 2013-06-19 2013-09-18 齐鲁工业大学 一种制备谷氨酸脱羧酶的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004137A1 (fr) * 1993-07-28 1995-02-09 Novo Nordisk A/S Composition stable

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004137A1 (fr) * 1993-07-28 1995-02-09 Novo Nordisk A/S Composition stable

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 103, No. 23, 9 December 1985, (Columbus, Ohio, USA), KARASAWA KEN et al., "Purification and Characterization of Lysophospholipase L2 of Escherichia Coli K-12", page 299, Abstract No. 192009z; & J. BIOCHEM., 1985, 98(4), 1117-1125. *
CHEMICAL ABSTRACTS, Volume 106, No. 17, 27 April 1987, (Columbus, Ohio, USA), WONG REX K.M. et al., "The Efficiency of Various Detergents for Extraction and Stabilization of Acetylcholinesterase from Bovine Erythrocytes", page 303, Abstract No. 134172y; & BIOCHEM. CELL BIOL., 1987, 65(1), 8-18. *
CHEMICAL ABSTRACTS, Volume 122, No. 11, 12 Sept. 1994, (Columbus, Ohio, USA), RUSELL-HARDE DEAN, "The Use of Zwittergent 3-14 in the Purification of Recombinant Human Interferon-beta Ser 17 (Betaseron)", page 850, Abstract No. 130430p; & J. INTERFERON CYTOKINE RES., 1995, 15(1), 31-37. *
CHEMICAL ABSTRACTS, Volume 122, No. 14, 3 April 1995, (Columbus, Ohio, USA), page 1239, Abstract No. 177437m; & JP,A,06 229 994 (KO FUMIJI et al.) 19 August 1994. *
CHEMICAL ABSTRACTS, Volume 95, No. 1, 6 July 1981, (Columbus, Ohio, USA), BAILYES ELAINE M. et al., "The Use of a Zwitterionic Detergent in the Solubilization and Purification of the Intrinsic Membrane Protein 5'-Nucleotidase", page 2382, Abstract No. 2386r; & BIOCHEM. SOC. TRANS., 1981, 9(1), 140-141. *
DIALOG INFORMATION SERVICES, File Medline, Dialog Accession No. 07758833, Medline Accession No. 94272982, TURSKY T. et al., "Glutamic Acid Decarboxylase in the Brain, Pancreas and Kidneys. Comparison of its Properties"; & BRATISL. LEK. LISTY (SLOVAKIA), Aug. 1993, 94(8), p439-43. *
METHODS IN ENZYMOLOGY, Vol. 182, Edited by MURRAY P. DEUTSCHER, "Guide to Protein Purification", pages 505-507. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027496A1 (fr) * 1998-11-09 2000-05-18 Knut Irgum Procede de chromatographie, et substance de garniture de la colonne utilisee dans le cadre dudit procede
US6884345B1 (en) 1998-11-09 2005-04-26 Knut Irgum Chromatography method and a column material useful in said method
EP1606404A4 (fr) * 2003-03-12 2006-04-12 Assay Designs Inc Dosage de phosphokinase
CN103305495A (zh) * 2013-06-19 2013-09-18 齐鲁工业大学 一种制备谷氨酸脱羧酶的方法

Also Published As

Publication number Publication date
EP0977835A1 (fr) 2000-02-09
AU7353298A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
Maury et al. Finnish hereditary amyloidosis: amino acid sequence homology between the amyloid fibril protein and human plasma gelsoline
CN110526982B (zh) 一种人胰高血糖素样肽-1类似物融合蛋白的纯化方法
JP5437378B2 (ja) ヒャッポダ由来のヘモコアグラーゼ
US5196323A (en) Process for preparing and purifying alpha-interferon
JPS6163295A (ja) 免疫インタ−フエロンの製法
WO1994024272A1 (fr) Procede de purificatin de collagenase
JPH10500843A (ja) コンドロイチナーゼｉおよびｉｉ、その製造法および用途
Mochida et al. Structural features of the 26S proteasome complex isolated from rat testis and sperm tail
WO1998049279A1 (fr) Utilisation de detergent/tensioactiof zwitterionique pour purifier l'acide glutamique decarboxylase (gad) et composition contenant cette enzyme gad
Sachdev et al. Isolation and characterization of glycoproteins from canine tracheal mucus
AU2014326257B2 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CN1263465C (zh) 结合APP的铜结合位点和/或发挥抑制淀粉样Aβ肽释放作用的铜激动剂
Treadwell et al. Purification of the ‘link proteins’ from bovine articular cartilage and comparison with ‘link proteins’ from nasal septum
CN1159438C (zh) 一种尖吻蝮蛇毒凝血酶及其生产方法
US5731186A (en) Method for the production of rDSPA α1
TW202346582A (zh) 一種凝血因子ｘ啟動酶及其應用
CN111065735A (zh) 用于纯化硫酸酯酶蛋白的方法
CN109265553B (zh) 一种细胞珠蛋白与方格星虫纤溶酶的融合蛋白
Elce Calpain methods and protocols
CN113480632A (zh) 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺
JPH01230522A (ja) トランスフォーミンググロウスファクター―βの精製方法
EP0700929A2 (fr) Peptides dérivés de allergènes du pollen de cèdre et leur applications
RU2683950C1 (ru) Способ очистки рекомбинантного тканевого активатора плазминогена для медицинского применения
Green et al. Purification, crystallization and preliminary X-ray investigation of aqualysin I, a heat-stable serine protease
EP0175786A1 (fr) Chymopapaine b pure: procede industriel et composition therapeutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998920768

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09403691

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998920768

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546875

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998920768

Country of ref document: EP